Personalized treatment for rifampicin-resistant TB
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of TB that is resistant to rifampicin but not to fluoroquinolones, confirmed by a lab test.
- You are 14 years or older.
- You are willing to have home visits and phone calls, and to tell the study team if you move.
- You can provide consent (or have a parent or guardian do so if you are a minor).
- Your liver, kidney, and blood counts are within safe ranges (checked by blood tests).
- If you have HIV, your CD4 count is at least 50 and you are on or starting dolutegravir-based HIV treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter treatment for tuberculosis (TB) using a combination of three medicines: bedaquiline, moxifloxacin, and pyrazinamide. If you have TB in your lungs, this could be a way to treat it more quickly than the standard longer course.
This study tests new combinations of drugs for treating pulmonary tuberculosis (TB). The goal is to find more effective and safer treatments than the current standard.
This trial studies whether a rifapentine-based TB regimen can work just as well while shortening treatment time. It’s for people with rifampicin-sensitive, smear-positive lung tuberculosis.
This study tests whether using a detailed sputum test to guide treatment for drug-resistant tuberculosis (TB) leads to better outcomes. Participants' treatment is tailored based on the specific drug resistance found, which may help them recover faster and reduce side effects.
This study tests a new medicine called sorfequiline, given in a combination regimen, to treat adults with drug-sensitive TB. It aims to see if sorfequiline can work as well as or better than standard treatment and shorten the time to cure.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
Hear when a new Tuberculosis, Pulmonary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.